Format

Send to

Choose Destination
Vet Immunol Immunopathol. 2009 Mar 15;128(1-3):178-83. doi: 10.1016/j.vetimm.2008.10.299. Epub 2008 Oct 17.

Camelid immunoglobulins and nanobody technology.

Author information

1
Laboratory of Cellular and Molecular Immunology, Department of Molecular and Cellular Interactions, VIB, Vrije Universiteit Brussel, Brussels, Belgium. svmuylde@vub.ac.be

Abstract

It is well established that all camelids have unique antibodies circulating in their blood. Unlike antibodies from other species, these special antibodies are devoid of light chains and are composed of a heavy-chain homodimer. These so-called heavy-chain antibodies (HCAbs) are expressed after a V-D-J rearrangement and require dedicated constant gamma-genes. An immune response is raised in these so-called heavy-chain antibodies following classical immunization protocols. These HCAbs are easily purified from serum, and the antigen-binding fragment interacts with parts of the target that are less antigenic to conventional antibodies. Since the antigen-binding site of the dromedary HCAb is comprised in one single domain, referred to as variable domain of heavy chain of HCAb (VHH) or nanobody (Nb), we designed a strategy to clone the Nb repertoire of an immunized dromedary and to select the Nbs with specificity for our target antigens. The monoclonal Nbs are well produced in bacteria, are very stable and highly soluble, and bind their cognate antigen with high affinity and specificity. We have successfully developed recombinant Nbs for research purposes, as probe in biosensors, to diagnose infections, and to treat diseases like cancer or trypanosomosis.

PMID:
19026455
DOI:
10.1016/j.vetimm.2008.10.299
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center